Institutional investors purchased a net $7.6 million shares of TXMD during the quarter ended June 2017. This may signal that the smart money is gaining interest in this company as the 77.17% of shares outstanding that institutional investors hold is actually below the Pharmaceuticals: Generic industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
STIFEL NICOLAUS & CO., INC. (INV... Bought 1.6 Million shares of TherapeuticsMD Inc
THE BOSTON COMPANY ASSET MANAGEM... Bought 1.6 Million shares of TherapeuticsMD Inc
JPMORGAN INVESTMENT MANAGEMENT, ... Bought 1.4 Million shares of TherapeuticsMD Inc